The global oncolytic virus therapy market is estimated to be valued at US$ 9.39 million in 2023 and is expected to exhibit a CAGR of 25.1% over the forecast period of 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Oncolytic virus therapy is a type of immunotherapy that uses viruses to invade and kill cancer cells. These viruses are modified in a way that they selectively infect and replicate within tumor cells, leading to their destruction. This therapy offers several advantages over traditional cancer treatments, including targeted action, minimal side effects, and the potential to stimulate the body's own immune response against cancer.
Market Key Trends:
One key trend in the oncolytic virus therapy market is the development of genetically modified viruses for enhanced therapeutic efficacy. Researchers are focused on engineering viruses to increase their tumor specificity, improve their replication rate within cancer cells, and enhance their ability to stimulate the immune system. By making these modifications, oncolytic virus therapy has the potential to become a more effective and targeted treatment option for various types of cancer.
PEST Analysis:
Political: The political landscape can have a significant impact on the oncolytic virus therapy market. Government regulations and policies regarding drug approvals and clinical trials can shape the market dynamics. Additionally, political stability and trade agreements between nations can affect the global market and its growth potential.
Economic: The economic factors influencing the oncolytic virus therapy market include healthcare expenditures, insurance coverage, and affordability of treatments. The market is also influenced by the overall economic growth of countries, as it impacts healthcare infrastructure and investment in research and development.
Social: Social factors such as changing demographics, lifestyle choices, and awareness about cancer treatment options can influence the demand for oncolytic virus therapy. Altering social attitudes towards alternative cancer treatments and increasing acceptance of innovative therapies can drive market growth.
Technological: The oncolytic virus therapy market heavily relies on advancements in technology and biotechnology research. Technological factors, such as gene editing techniques, viral engineering, and personalized medicine, play a crucial role in driving innovation and the development of effective therapies.
Key Takeaways:
The global Oncolytic Virus Therapy Market Growth is expected to witness significant growth, exhibiting a CAGR of 25.1% from 2023 to 2030. This growth can be attributed to increasing investments in research and development activities, advancements in biotechnology, and rising prevalence of cancer worldwide.
In terms of regional analysis, North America is expected to be the fastest-growing and dominating region in the oncolytic virus therapy market. The region's strong healthcare infrastructure, favorable regulatory environment, and high R&D investments contribute to its market dominance. Furthermore, the presence of key players and collaborations with research institutions bolster the market growth in North America.
Key players operating in the oncolytic virus therapy market include Amgen Inc., Merck & Co., Inc., Oncolytics Biotech Inc., Targovax, PsiOxus Therapeutics Ltd., Vyriad, Inc., SillaJen Biotherapeutics, Cold Genesys Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Replimune Group Inc., Genelux Corporation, Transgene SA, VCN Biosciences, and Lokon Pharma AB. These companies have a strong presence in the market and are actively involved in research, development, and commercialization of oncolytic virus therapies.
Read More,
Comments
0 comment